CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Curis, Inc.
Curis, Inc.
Kelonia Therapeutics, Inc.
Orca Biosystems, Inc.
Cellectar Biosciences, Inc.
Center for International Blood and Marrow Transplant Research
Mayo Clinic
University of Heidelberg Medical Center
Center for International Blood and Marrow Transplant Research
UNC Lineberger Comprehensive Cancer Center
UNC Lineberger Comprehensive Cancer Center
Pfizer
UNC Lineberger Comprehensive Cancer Center
UNC Lineberger Comprehensive Cancer Center
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
UNC Lineberger Comprehensive Cancer Center
Novartis
Juno Therapeutics, a Subsidiary of Celgene
The Lymphoma Academic Research Organisation
Acerta Pharma BV
Oncternal Therapeutics, Inc
Shenzhen University General Hospital
University Hospital Muenster
Astex Pharmaceuticals, Inc.
OriCell Therapeutics Co., Ltd.
Amgen
Kyowa Kirin Co., Ltd.
AO GENERIUM
Nordic Nanovector
Intellia Therapeutics
Celgene
Sunnybrook Health Sciences Centre
Oncternal Therapeutics, Inc
Celularity Incorporated
Takeda
miRagen Therapeutics, Inc.
UNC Lineberger Comprehensive Cancer Center
University of California, San Francisco
Merck Sharp & Dohme LLC
Takeda
miRagen Therapeutics, Inc.
Seagen Inc.
Swiss Pediatric Oncology Group
Seagen Inc.
City of Hope Medical Center
Fudan University
University of North Carolina, Chapel Hill
Amgen Research (Munich) GmbH
Amgen Research (Munich) GmbH
Amgen Research (Munich) GmbH
Seagen Inc.